Ipatasertib (GDC-0068) is also effective both in cancer cell lines and in xenograft models with activation of Akt due to complete loss of PTEN (PTEN-null), decreased expression of PTEN or mutations in PIK3CA [127]. The gene discussed is AKT1; the disease is cancer.